Skip to main content
Start of content

INDU Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Minutes of Proceedings

Standing Committee on Industry and Technology (INDU)
44th Parliament, 1st Session
Meeting 17
Friday, April 8, 2022, 1:03 p.m. to 3:08 p.m.
Webcast
Presiding
Joël Lightbound, Chair (Liberal)

Expand AllCollapse All
• Chandra Arya for Viviane Lapointe (Liberal)
• Bonita Zarrillo for Brian Masse (NDP)
Library of Parliament
• Sarah Lemelin-Bellerose, Analyst
• Scott McTaggart, Analyst
Domestic Manufacturing Capacity for a COVID-19 Vaccine
Department of Industry
• Eric Costen, Senior Assistant Deputy Minister, Industry Sector
• Rodrigo Arancibia, Senior Director, Life Sciences and Biomanufacturing Branch
• Darryl C. Patterson, Director General, Life Sciences and Biomanufacturing Branch
• Daniel Quinn, Director, Research Infrastructure and Outreach, Science and Research Sector
National Research Council of Canada
• Maria Aubrey, Vice-President, Strategic Initiatives
• Lakshmi Krishnan, Vice-President, Life Sciences
As an individual
• Dr. Alain Lamarre, Full Professor, Institut national de la recherche scientifique
BioNiagara
• John R. Fulton, President, Spokesperson and Representative for Biolyse Pharma Corporation
BIOTECanada
• Andrew Casey, President and Chief Executive Officer
BioVectra Inc.
• Oliver Technow, Chief Executive Officer
• Dr. Marc Sauer, Vice-President, Process Science and Development Services
Vaccine and Infectious Disease Organization - International Vaccine Centre
• Dr. Volker Gerdts, Director and Chief Executive Officer
Pursuant to Standing Order 108(2) and the motion adopted by the committee on Wednesday, January 26, 2022, the committee commenced its study of domestic manufacturing capacity for a COVID-19 vaccine.

Eric Costen and Maria Aubrey made statements and, with Rodrigo Arancibia, Darryl C. Patterson, Daniel Quinn, Lakshmi Krishnan, answered questions.

At 2:03 p.m., the sitting was suspended.

At 2:09 p.m., the sitting resumed.

At 2:09 p.m., Michael Kram took the Chair.

Alain Lamarre, John R. Fulton, Andrew Casey, Oliver Technow, Marc Sauer and Volker Gerdts made statements and answered questions.

At 3:08 p.m., Joël Lightbound took the Chair.

Committee Business
The committee proceeded to the consideration of matters related to committee business.

By unanimous consent, it was agreed, — That, pursuant to Standing Order 108(2), the committee undertake a study on the labour shortage and the productivity of our small and medium-sized enterprises (SME), focusing on (1) labour shortage; (2) regulatory requirements and bureaucracy; (3) supply chain constraints; (4) inflation; (5) competitiveness; (6) the reform of the Competition Act and any other competition-related matters, and that the evidence and documentation received by the committee during the 43rd Parliament on the subject be taken into consideration by the committee in the current session.

At 3:08 p.m., the committee adjourned to the call of the Chair.



Michael MacPherson
Clerk of the committee